登录 | 注册    关注公众号  
微信公众号
搜索
 > 【CCL22】

CCL22信息

英文名称:ATP Binding Cassette Subfamily D Member 1
中文名称:ATP结合盒家族D成员1
靶点别称:ATP Binding Cassette Subfamily D Member 1,Adrenoleukodystrophy Protein,ATP-Binding Cassette Sub-Family D Member 1,ALDP,ATP-Binding Cassette, Sub-Family D (ALD), Member 1,ABC42,ABCD1,AMN,ALD,ATP Binding Cassette Transporter, Subfamily D, Member 1,Adrenoleukodystrophy
上市药物数量:1
临床药物数量:2
最高研发阶段:批准上市

CCL22产品列表

产品库
物种
标签
属性
货号 物种 产品描述 蛋白结构 纯度 活性
CC2-H5257
Human
Human CCL22 / MDC Protein, Fc Tag
ACRO质量管理体系
 
评论(0)
 

CCL22 分子别名

MDC/ABCD-1/SCYA22/STCP-1/DC/B-CK/A-152E5.1

CCL22 分子背景

This antimicrobial gene is one of several Cys-Cys (CC) cytokine genes clustered on the q arm of chromosome 16. Cytokines are a family of secreted proteins involved in immunoregulatory and inflammatory processes. The CC cytokines are proteins characterized by two adjacent cysteines. The cytokine encoded by this gene displays chemotactic activity for monocytes, dendritic cells, natural killer cells and for chronically activated T lymphocytes. It also displays a mild activity for primary activated T lymphocytes and has no chemoattractant activity for neutrophils, eosinophils and resting T lymphocytes. The product of this gene binds to chemokine receptor CCR4. This chemokine may play a role in the trafficking of activated T lymphocytes to inflammatory sites and other aspects of activated T lymphocyte physiology.

CCL22 前沿进展

CCL22上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Elivaldogene autotemcel 艾基干赛 批准上市 Bluebird Bio Inc, Inserm Lenti-D, Skysona United States 肾上腺脑白质营养不良 Bluebird Bio Inc 2021-07-27 肾上腺脑白质营养不良 详情

CCL22临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
TYF-ABCD1 TYF-ABCD1 临床阶段不明 深圳市免疫基因治疗研究院 肾上腺脑白质营养不良 详情
Pozetaldogene ormesparvovec SBT-101 临床二期 SwanBio Therapeutics Ltd 肾上腺脑白质营养不良 详情

消息提示

请输入您的联系方式,再点击提交!

确定